PMID- 14632845
OWN - NLM
STAT- MEDLINE
DCOM- 20040129
LR  - 20220331
IS  - 1464-4096 (Print)
IS  - 1464-4096 (Linking)
VI  - 92
IP  - 9
DP  - 2003 Dec
TI  - Comparison of multitarget fluorescence in situ hybridization in urine with other 
      noninvasive tests for detecting bladder cancer.
PG  - 911-4
AB  - OBJECTIVES: To present a single-centre study investigating aneuploidy at 
      chromosomes 3, 7, 17 and 9p21 (e.g. loss at 9p21) using a multitarget 
      fluorescence in situ hybridization (FISH) system, as identifying genetic 
      alterations in urine specimens is a promising approach for the noninvasive 
      detection of bladder cancer. PATIENTS AND METHODS: Urine samples from 103 
      patients were evaluated, including those from 46 with histologically confirmed 
      urothelial carcinoma, two with other urological malignancies, and 55 who acted as 
      controls. The urine samples were taken before any manipulation. The validity of 
      FISH (Urovision, Vysis, Downers Grove, Ill, USA) was compared with other 
      noninvasive urine tests, including the BTA-Stat test, the nuclear matrix protein 
      (NMP)-22 test, and immunocytology against 486p3/12 and LewisX. Those evaluating 
      the tests were unaware of the clinical and histopathological data. FISH was 
      considered positive if five or more urinary cells had gains of two or more 
      chromosomes. The threshold for the urine tests were 10 U/mL (NMP-22), 30% 
      positive cells (486p3/12), or 5% positive cells, respectively (LewisX). RESULTS: 
      The sensitivity was 69% (FISH), 67% (BTA-Stat), 69% (486p3/12), 96% (LewisX) and 
      71% (NMP22), respectively; the respective specificity was 89%, 78%, 76%, 33% and 
      66%. CONCLUSION: Multitarget FISH had a better specificity than the other urine 
      markers but because of its inadequate sensitivity it does not seem to be powerful 
      enough to replace endoscopy. Optimizing the marker panel could provide a higher 
      sensitivity.
FAU - Friedrich, M G
AU  - Friedrich MG
AD  - Department of Urology, University Hospital Hamburg-Eppendorf, University of 
      Hamburg, Germany. friedrich@uke.uni-hamburg.de
FAU - Toma, M I
AU  - Toma MI
FAU - Hellstern, A
AU  - Hellstern A
FAU - Pantel, K
AU  - Pantel K
FAU - Weisenberger, D J
AU  - Weisenberger DJ
FAU - Noldus, J
AU  - Noldus J
FAU - Huland, H
AU  - Huland H
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
SB  - IM
MH  - Aneuploidy
MH  - Carcinoma, Transitional Cell/diagnosis/*genetics/urine
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*standards
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Urinary Bladder Neoplasms/diagnosis/*genetics/urine
EDAT- 2003/11/25 05:00
MHDA- 2004/01/30 05:00
CRDT- 2003/11/25 05:00
PHST- 2003/11/25 05:00 [pubmed]
PHST- 2004/01/30 05:00 [medline]
PHST- 2003/11/25 05:00 [entrez]
AID - 4528 [pii]
AID - 10.1111/j.1464-410x.2003.04528.x [doi]
PST - ppublish
SO  - BJU Int. 2003 Dec;92(9):911-4. doi: 10.1111/j.1464-410x.2003.04528.x.